Beijing Med-Pharm Corp. to Market Ferriprox(R) in China; Signs Five Year Exclusive Agreement with Canada’s Largest Pharmaceutical Company

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Beijing Med-Pharm Corporation (NASDAQ:BJGP) (“Beijing Med-Pharm” or the “Company”), today announced that it has signed an exclusive, renewable five year agreement with Apotex Inc., to market and distribute Ferriprox® (Deferiprone) in the People's Republic of China.